Kevin Chang
Partner,
Head of our Greater China Healthcare & Life Sciences practice.
À propos de Kevin
Expertise
Kevin Chang is the head of our Greater China Healthcare & Life Sciences practice and a member of our Private Equity practice.
Kevin regularly advises clients on organization, strategy and transformation, as well as both commercial and launch excellence. His recent client engagements have involved due diligence and sector screening and review efforts for private equity clients, as well as adjacency and business unit strategy across pharmaceuticals and biotechnology.
While with the firm, Kevin has led a commercial excellence exercise for one of the world's leading IVD manufacturers, which doubled the company’s business in China in 5 years.
He is also deeply involved with our local pro bono efforts.
Kevin holds a B.A. in Economics from Cornell University.
Recent Insights
- “Medtech M&A,” M&A Report, 9 janvier 2026, Rapport
- “Empowering Biotech Innovation in Asia-Pacific,” Rapport, 31 juillet 2025
- “Investors Favor Asia-Pacific Markets as Biotech Destinations Amid US-China Tensions,” Press release, 31 juillet 2025
- “Why ESG Matters for Medtech in the Asia-Pacific Region,” Rapport, 25 octobre 2023
- “Healthcare and Life Sciences M&A,” M&A Report, 31 janvier 2023, Rapport